Leukemia Research
Volume 29, Issue 7 , Pages 793-802 , July 2005

The tyrosine kinase inhibitors imatinib and AG957 reverse multidrug resistance in a chronic myelogenous leukemia cell line

  • Daniella Yeheskely-Hayon

      Affiliations

    • Department of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel
    • ,
  • Ronit Regev

      Affiliations

    • Department of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel
    • ,
  • Gera D. Eytan

      Affiliations

    • Department of Biology, Technion-Israel Institute of Technology, Haifa 32000, Israel
    • Corresponding Author InformationCorresponding author. Tel.: +972 4 8293406; fax: +972 4 8225153.
    • ,
  • Eldad J. Dann

      Affiliations

    • Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Bruce Rappaport Faculty of Medicine, Haifa 31096, Israel

Received 4 March 2004 ,Accepted 17 December 2004.

References 

  1. Epner DE, Koeffler HP. Molecular genetic advances in chronic myelogenous leukaemia. Ann Intern Med. 1990;113(1):3–6
  2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079–1082
  3. Faderl S, Kantarjian HM, Talpaz M. Chronic myelogenous leukemia: update on biology and treatment. Oncology (Huntingt). 1999;13(2):169–180[discussions 81, 84]
  4. Gordon MY, Dazzi F, Marley SB, Lewis JL, Nguyen D, Grand FH, et al. Cell biology of CML cells. Leukemia. 1999;13(Suppl. 1):S65–S71
  5. Gazit A, Yaish P, Gilon C, Levitzki A. Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989;32(10):2344–2352
  6. Anafi M, Gazit A, Zehavi A, Ben-Neriah Y, Levitzki A. Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate. Blood. 1993;82(12):3524–3529
  7. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267(5205):1782–1788
  8. Carlo-Stella C, Regazzi E, Sammarelli G, Colla S, Garau D, Gazit A, et al. Effects of the tyrosine kinase inhibitor AG957 and an anti-Fas receptor antibody on CD34(+) chronic myelogenous leukemia progenitor cells. Blood. 1999;93(11):3973–3982
  9. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA. Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs. 1994;5(2):213–222
  10. Bhatia R, Munthe HA, Verfaillie CM. Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores betal integrin-mediated adhesion and inhibitors signaling in chronic myelogenous leukemia hematopoietic progenitors. Leukemia. 1998;12(11):1708–1717
  11. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2(5):561–566
  12. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood. 1997;90(9):3691–3698
  13. Gora-Tybor J, Deininger MW, Goldman JM, Melo JV. The susceptibility of Philadelphia chromosome positive cells to FAS-mediated apoptosis is not linked to the tyrosine kinase activity of BCR-ABL. Br J Haematol. 1998;103(3):716–720
  14. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med. 2001;344(14):1031–1037
  15. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14):1038–1042
  16. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340(17):1330–1340[see comments]
  17. Fang G, Kim CN, Perkins CL, Ramadevi N, Winton E, Wittmann S, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 2000;96(6):2246–2253
  18. Bedi A, Barber JP, Bedi GC, el-Deiry WS, Sidransky D, Vala MS, et al. BCR-ABL-mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: a mechanism of resistance to multiple anticancer agents. Blood. 1995;86(3):1148–1158
  19. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. BCR-ABL maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83(5):1179–1187[published erratum appears in Blood 1994;83(12):3835]
  20. Amarante-Mendes GP, Naekyung Kim C, Liu L, Huang Y, Perkins CL, Green DR, et al. Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome C and activation of caspase-3. Blood. 1998;91(5):1700–1705
  21. Carter A, Dann EJ, Katz T, Shechter Y, Oliven A, Regev R, et al. Cells from chronic myelogenous leukaemia patients at presentation exhibit multidrug resistance not mediated by either MDR1 or MRP1. Br J Haematol. 2001;114(3):581–590
  22. Homolya L, Hollo Z, Germann UA, Pastan I, Gottesman MM, Sarkadi B. Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem. 1993;268(29):21493–21496
  23. Koeffler HP, Golde DW. Human myeloid leukemia cell lines: a review. Blood. 1980;56(3):344–350
  24. Marie JP, Faussat-Suberville AM, Zhou D, Zittoun R. Daunorubicin uptake by leukemic cells: correlations with treatment outcome and mdr1 expression. Leukemia. 1993;7(6):825–831
  25. Regev R, Eytan GD. Flip-flop of doxorubicin across erythrocyte and lipid membranes. Biochem Pharmacol. 1997;54(10):1151–1158
  26. Rosenfeld C, Goutner A, Choquet C, Venuat AM, Kayibanda B, Pico JL, et al. Phenotypic characterisation of a unique non-T, non-B acute lymphoblastic leukaemia cell line. Nature. 1977;267(5614):841–843
  27. Zheng B, Chambers TC, Raynor RL, Markham PN, Gebel HM, Vogler WR, et al. Human leukemia K562 cell mutant (K562/OA200) selected for resistance to okadaic acid (protein phosphatase inhibitor) lacks protein kinase C-epsilon, exhibits multidrug resistance phenotype, and expresses drug pump P-glycoprotein. J Biol Chem. 1994;269(16):12332–12338
  28. Boren J, Cascante M, Marin S, Comin-Anduix B, Centelles JJ, Lim S, et al. Gleevec (STI571) influences metabolic enzyme activities and glucose carbon flow toward nucleic acid and fatty acid synthesis in myeloid tumor cells. J Biol Chem. 2001;276(41):37747–37753
  29. Reichert A, Heisterkamp N, Daley GQ, Groffen J. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001;97(5):1399–1403

PII: S0145-2126(05)00032-9

doi: 10.1016/j.leukres.2004.12.007

Leukemia Research
Volume 29, Issue 7 , Pages 793-802 , July 2005

Article Tools

* Image Usage & Resolution